![](/images/graphics-bg.png)
Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival Postprogression
المؤلفون المشاركون
Maeda, Shin
Kondo, Masaaki
Numata, Kazushi
Hara, Koji
Nozaki, Akito
Fukuda, Hiroyuki
Chuma, Makoto
Tanaka, Katsuaki
المصدر
Gastroenterology Research and Practice
العدد
المجلد 2017، العدد 2017 (31 ديسمبر/كانون الأول 2017)، ص ص. 1-10، 10ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2017-06-22
دولة النشر
مصر
عدد الصفحات
10
التخصصات الرئيسية
الملخص EN
Background.
Sorafenib is a first-line treatment option for advanced hepatocellular carcinoma (HCC) patients; however, survival predictors upon progression have not been well characterized.
In the present study, we aimed to show the efficacy of multidisciplinary therapy for patients who had failed to respond to sorafenib treatment.
Methods.
Among 146 BCLC stage B or C HCC patients treated with sorafenib monotherapy between July 2009 and August 2014, the first radiological progression according to the modified RECIST was identified in 71 patients; factors predicting overall survival (OS) and survival postprogression (SPP) were analyzed in these patients.
Results.
The median OS and SPP for patients who failed to respond to sorafenib treatment were 10.5 and 6.2 months, respectively, and the SPP was strongly correlated with the OS (r=0.982, P<0.01, and R2=0.965).
The independent predictors of OS and SPP were identical.
The predictors of SPP were des-gamma-carboxy prothrombin, progression of portal vein thrombosis, and subsequent second-line or additional treatment.
Conclusions.
SPP is closely associated with OS and might be notable in patients who have failed to respond to initial sorafenib treatment.
Furthermore, interventions consisting of other treatment options upon the appearance of progression might prolong OS.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Kondo, Masaaki& Numata, Kazushi& Hara, Koji& Nozaki, Akito& Fukuda, Hiroyuki& Chuma, Makoto…[et al.]. 2017. Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival Postprogression. Gastroenterology Research and Practice،Vol. 2017, no. 2017, pp.1-10.
https://search.emarefa.net/detail/BIM-1156484
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Kondo, Masaaki…[et al.]. Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival Postprogression. Gastroenterology Research and Practice No. 2017 (2017), pp.1-10.
https://search.emarefa.net/detail/BIM-1156484
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Kondo, Masaaki& Numata, Kazushi& Hara, Koji& Nozaki, Akito& Fukuda, Hiroyuki& Chuma, Makoto…[et al.]. Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival Postprogression. Gastroenterology Research and Practice. 2017. Vol. 2017, no. 2017, pp.1-10.
https://search.emarefa.net/detail/BIM-1156484
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1156484
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)